嵌合抗原受体
髓系白血病
医学
微小残留病
造血干细胞移植
免疫学
移植
疾病
白血病
免疫疗法
抗原
肿瘤科
癌症研究
免疫系统
内科学
作者
Bin Gu,Jianhong Chu,Depei Wu
标识
DOI:10.1007/s11684-020-0763-z
摘要
Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cell tumors, prompting scientists and doctors to exploit this strategy to treat other tumor types. Acute myeloid leukemia (AML) is a group of heterogeneous myeloid malignancies. Relapse remains the main cause of treatment failure, especially for patients with intermediate or high risk stratification. Allogeneic hematopoietic stem cell transplantation could be an effective therapy because of the graft-versus-leukemia effect, which unfortunately puts the patient at risk of serious complications, such as graft-versus-host disease. Although the identification of an ideal target antigen for AML is challenging, CAR T therapy remains a highly promising strategy for AML patients, particularly for those who are ineligible to receive a transplantation or have positive minimal residual disease. In this review, we focus on the most recent and promising advances in CAR T therapies for AML.
科研通智能强力驱动
Strongly Powered by AbleSci AI